NCT06916091CompletedPhase 1
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
A Phase 1, Investigator- and Participant-Blinded, Placebo Controlled, Randomized, Single Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
Source: ClinicalTrials.gov · Last updated 19 Nov 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much Eloralintide gets into the bloodstream and how long it takes the body to eliminate it. The study will last approximately 10 weeks excluding a screening period.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 1 Apr 2025
- Start date
- 21 Apr 2025
- Primary completion date
- 9 Sept 2025
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity
- NCT number
- NCT06916091
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 30
- From 21 Apr 2025 to the primary completion date, 9 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have any of the following abnormal blood pressure (BP) and/or pulse rate at screening, constituting a risk when taking the investigational product with minor deviations judged to be acceptable by the investigator:
- Supine BP \> 160/90 millimeter mercury (mmHg)
- Supine pulse rate \< 50 or \> 100 beats per minute (bpm)
- Orthostatic hypotension
- Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs
- Regularly use known drugs of abuse and/or show positive findings on drug screening that are not consistent with the medical history or concomitant medication history
- Have donated blood of more than 450 mL within the previous 3 months of study screening, or intend to donate blood during the course of the study
Other illness
- Have known allergies to related compounds of eloralintide
- Have a history of chronic medical conditions involving the heart, liver, or kidneys
- Have a medical history or current evidence of clinically significant cardiac condition
Other
- Are pregnant, or intend to become pregnant or to breastfeed during the study
Who the study is looking for
- Chinese participants. To qualify as Chinese, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China
- Have had a stable body weight for 3 months prior to screening. Participants with body weight change of less than 5% will be allowed
- Have not modified diet or adopted any nutritional lifestyle modification for 3 months before randomization
- Have clinical laboratory test results within a normal range for the population or investigative site at screening and lead-in, or results with acceptable deviations that are judged to be not clinically significant by the investigator
- Have a body mass index (BMI) within the range 27 to 40 kilogram per square meter (kg/m²)
Age in the registry: 21 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lilly Centre for Clinical Pharmacology Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.